Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction

Among patients receiving intravitreal anti–vascular endothelial growth factor (anti-VEGF) who experience acute stroke or myocardial infarction (MI), is pericardiovascular event (CVE) treatment associated with mortality or major sequelae?In a multicenter electronic health record network cohort, 1526 and 1523 matched pairs with stroke and MI, respectively, were analyzed. Peri-CVE treatment was not associated with a worse mortality or morbidity outcome, and no differences in outcomes among commonly used anti-VEGF agents from 2005 through 2025 (aflibercept, bevacizumab, and ranibizumab) were identified.These findings reveal that peri-CVE anti-VEGF was not associated with harm and may be continued without altering timing or agent selection.

Corresponding Author: Christina Y. Weng, MD, MBA, Vitreoretinal Diseases christina.weng@bcm.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.